Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/29050
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCapodanno, Davide-
dc.contributor.authorHuber, Kurt-
dc.contributor.authorMehran, Roxana-
dc.contributor.authorLip, Gregory Y. H.-
dc.contributor.authorFaxon, David P.-
dc.contributor.authorGranger, Christopher B.-
dc.contributor.authorVRANCKX, Pascal-
dc.contributor.authorLopes, Renato D.-
dc.contributor.authorMontalescot, Gilles-
dc.contributor.authorCannon, Christopher P.-
dc.contributor.authorTen Berg, Jurien-
dc.contributor.authorGersh, Bernard J.-
dc.contributor.authorBhatt, Deepak L.-
dc.contributor.authorAngiolillo, Dominick J.-
dc.date.accessioned2019-08-27T09:56:16Z-
dc.date.available2019-08-27T09:56:16Z-
dc.date.issued2019-
dc.identifier.citationJOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 74(1), p. 83-99-
dc.identifier.issn0735-1097-
dc.identifier.urihttp://hdl.handle.net/1942/29050-
dc.description.abstractMost patients with atrial fibrillation (AF) and risk factors for stroke require oral anticoagulation (OAC) to decrease the risk of stroke or systemic embolism. This is now best achieved with direct oral anticoagulants that decrease the risk of intracranial bleeding compared with vitamin K antagonists. Of note, approximately 5% to 10% of patients undergoing percutaneous coronary intervention have AF, which complicates antithrombotic therapy in daily practice, because the guidelines recommend that these patients also receive dual antiplatelet therapy (DAPT) to reduce the risk of ischemic complications. However, combining OAC with DAPT, a strategy also known as triple antithrombotic therapy, is known to increase the risk of bleeding compared with the use of OAC or DAPT alone. Studies of direct oral anticoagulants are now emerging that show the favorable safety profile of double antithrombotic therapy with OAC and a P2Y(12) inhibitor in comparison with triple antithrombotic therapy including the use of vitamin K antagonists. The scope of this review is to provide an update on this topic as well as to discuss future directions in the management of antithrombotic therapy after percutaneous coronary intervention in AF patients requiring chronic OAC. (C) 2019 by the American College of Cardiology Foundation.-
dc.description.sponsorshipFrom the aDivision of Cardiology, A.O.U. "Policlinico-Vittorio Emanuele," University of Catania, Catania, Italy; b3rd Medical Department, Cardiology and Intensive Care Medicine and Sigmund Freud University, Medical Faculty, Vienna, Austria; cCardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York; dLiverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom; eAalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark; fBrigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, Boston, Massachusetts; gDuke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina; hDepartment of Cardiology and Critical Care Medicine, Hartcentrum Hasselt, and faculty of Medicine and Life Sciences at the University of Hasselt, Hasselt, Belgium; iCardiology Department, Nimes University Hospital, ACTION Study Group, Montpellier University, Nimes, France; jDepartment of Cardiology, St. Antonius Hospital, Nieuwegein, the Netherlands; kMayo Clinic College of Medicine, Rochester, Minnesota; and the lDivision of Cardiology, University of Florida College of Medicine, Jacksonville, Florida. Dr. Capodanno has received speakers honoraria from Bayer, AstraZeneca, Daiichi-Sankyo, Pfizer, and Boehringer Ingelheim; and has received consulting fees from Abbott Vascular, Bayer, and Daiichi-Sankyo. Dr. Huber has received lecture fees from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, Eli Lilly, Pfizer, Portola, Sanofi, and The Medicines Company. Dr. Mehran has received institutional research funding from AstraZeneca, Bayer, Beth Israel Deaconess, Bristol-Myers Squibb/Sanofi, CSL Behring, Eli Lilly/Daiichi-Sankyo, Medtronic, Novartis, and OrbusNeich; has served as a consultant to Boston Scientific, Abbott Vascular, Medscape, Siemens Medical Solutions, Regeneron Pharmaceuticals (no fees), Roivant Sciences, and Sanofi; has served as an institutional consultant (payment to institution) for Abbott Vascular and Spectranetics/Phillips/Volcano Corporation; has served on the Executive Committee for Janssen Pharmaceuticals and Bristol-Myers Squibb; has received institutional (payment to institution) Advisory Board funding from Bristol-Myers Squibb and Novartis; has received Data and Safety Monitoring Board membership funding to his institution from Watermark Research; and has < 1% equity with Claret Medical and Elixir Medical. Dr. Lip has served as a consultant for Bayer/Janssen, Bristol-Myers Squibb/Pfizer, Medtronic, Boehringer Ingelheim, Novartis, Verseon, and Daiichi-Sankyo; and has received speaker's honoraria from Bayer, Bristol-Myers Squibb/Pfizer, Medtronic, Boehringer Ingelheim, and Daiichi-Sankyo. Dr. Faxon has received personal fees from Boston Scientific, Medtronic, and Baim. Dr. Granger has received personal fees from Janssen, Boston Scientific, and Medtronic; has received research grant support from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Medtronic, Daiichi-Sankyo, Janssen Pharmaceuticals, Bayer, Pfizer, Novartis, Population Health Research Institute, the U.S. Food and Drug Administration, and the National Heart, Lung, and Blood Institute; and has received consulting fees from Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, Medtronic, Merck & Co., Novartis, Pfizer, Daiichi-Sankyo, Rho Pharmaceuticals, Verseon, and Janssen Pharmaceuticals. Dr. Vranckx has received personal fees from AstraZeneca, Bayer Health Care, CLS Behring, and Daiichi-Sankyo. Dr. Lopes has received consulting fees from Amgen, Bayer, Boehringer Ingelheim, BristolMyers Squibb, GlaxoSmithKline, Medtronic, Pfizer, and Sanofi; and has received institutional grants from Bristol-Myers Squibb, GlaxoSmithKline, Medtronic, Pfizer, and Sanofi. Dr. Montalescot has received research grants to the institution or consulting/lecture fees from Abbott, Amgen, Actelion, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Beth Israel Deaconess Medical, Brigham Women's Hospital, Cardiovascular Research Foundation, Daiichi-Sankyo, Idorsia, Lilly, Europa, Elsevier, Federation Francaise de Cardiologie, ICAN, Medtronic, Journal of the American College of Cardiology, Lead-Up, Menarini, Merck Sharp & Dohme, Novo Nordisk, Pfizer, Sanofi, Servier, The Mount Sinai School, TIMI Study Group, and WebMD. Dr. Cannon has received institutional grants and personal fees from Boehringer Ingelheim and Bristol-Myers Squibb; institutional grants from Daiichi-Sankyo and Janssen; and honoraria from Amgen, Amarin, Merck, Alnylam, Kowa, Pfizer, Eisai Co., Ltd., Sanofi, and Regeneron. Dr. Ten Berg has received grant support, Advisory Board fees, consulting fees, and lecture fees from AstraZeneca; has received Advisory Board fees, consulting fees, and lectures fees from Eli Lilly, Daiichi-Sankyo, The Medicines Company, Accumetrics, Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer, and Bayer; and has received grant support from ZonMw and AstraZeneca. Dr. Gersh has received research contracts with Apple, AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi-Sankyo, Janssen, Novartis, GlaxoSmithKline, Medtronic Foundation, Pfizer, the U.S. Food and Drug Administration, and the National Institutes of Health; and has a consulting relationship with Abbvie, AstraZeneca, Bayer, BristolMyers Squibb, Boehringer Ingelheim, Boston Scientific, Gilead, Pfizer, Daiichi-Sankyo, Novartis, Medtronic, Merck, Novo Nordisk, and Roche Diagnostics. Dr. Bhatt has served on the Advisory Board of Cardax, Elsevier Practice Update Cardiology, Medscape Cardiology, PhaseBio, and Regado Biosciences; has served on the Board of Directors of Boston VA Research Institute, Society of Cardiovascular Patient Care, and TobeSoft; has served as Chair of the American Heart Association Quality Oversight Committee, NCDR-ACTION Registry Steering Committee, and the VA CART Research and Publications Committee; has served on the Data Monitoring Committees of Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi-Sankyo), and the Population Health Research Institute; has received honoraria from American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC. org; Vice-Chair, ACC Accreditation Committee), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI Clinical Trial Steering Committee funded by Boehringer Ingelheim), Belvoir Publications (Editor-in-Chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees), HMP Global (Editor-in-Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), Medtelligence/ReachMD (CME steering committees), Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national coleader, funded by Bayer), Slack Publications (Chief Medical Editor, Cardiology Today's Intervention), Society of Cardiovascular Patient Care (Secretary/Treasurer), and WebMD (CME Steering Committees); has served as Deputy Editor of Clinical Cardiology; has received research funding from Abbott, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, Eisai, Ethicon, Forest Laboratories, Idorsia, Ironwood, Ischemix, Lilly, Medtronic, PhaseBio, Pfizer, Regeneron, Roche, Sanofi, Synaptic, and The Medicines Company; has received royalties from Elsevier (Editor, Cardiovascular Intervention: A Companion to Braunwald's Heart Disease); has served as site coinvestigator for Biotronik, Boston Scientific, St. Jude Medical (now Abbott), and Svelte; has served as a Trustee of the American College of Cardiology; and has performed unfunded research for FlowCo, Fractyl, Merck, Novo Nordisk, PLx Pharma, and Takeda. Dr. Angiolillo has received consulting fees or honoraria as an individual from Amgen, Aralez, AstraZeneca, Bayer, Biosensors, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, Daiichi-Sankyo, Eli Lilly, Haemonetics, Janssen, Merck, PhaseBio, PLx Pharma, Pfizer, Sanofi, and The Medicines Company; has participated in review activities for CeloNova and St. Jude Medical; and has received institutional grants from Amgen, AstraZeneca, Bayer, Biosensors, CeloNova, CSL Behring, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Idorsia, Janssen, Matsutani Chemical Industry Co., Merck, Novartis, Osprey Medical, and Renal Guard Solutions. Stefan Hohnloser, MD, served as Guest Associate Editor for this paper.-
dc.language.isoen-
dc.publisherELSEVIER SCIENCE INC-
dc.rights2019 by the American College of Cardiology Foundation. Published by Elsevier.-
dc.subject.otheratrial fibrillation; coronary stenting; oral anticoagulant; oral antiplatelet-
dc.subject.otheratrial fibrillation; coronary stenting; oral anticoagulant; oral antiplatelet-
dc.titleManagement of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI JACC State-of-the-Art Review-
dc.typeJournal Contribution-
dc.identifier.epage99-
dc.identifier.issue1-
dc.identifier.spage83-
dc.identifier.volume74-
local.format.pages17-
local.bibliographicCitation.jcatA1-
dc.description.notes[Capodanno, Davide] Univ Catania, AOU Policlin Vittorio Emanuele, Div Cardiol, Catania, Italy. [Huber, Kurt] Sigmund Freud Univ, Dept Med 3, Cardiol & Intens Care Med, Vienna, Austria. [Huber, Kurt] Sigmund Freud Univ, Fac Med, Vienna, Austria. [Mehran, Roxana] Icahn Sch Med Mt Sinai, Cardiovasc Inst, New York, NY 10029 USA. [Lip, Gregory Y. H.] Univ Liverpool, Liverpool Ctr Cardiovasc Sci, Liverpool, Merseyside, England. [Lip, Gregory Y. H.] Liverpool Heart & Chest Hosp, Liverpool, Merseyside, England. [Lip, Gregory Y. H.] Aalborg Univ, Dept Clin Med, Aalborg Thrombosis Res Unit, Aalborg, Denmark. [Faxon, David P.; Cannon, Christopher P.; Bhatt, Deepak L.] Harvard Med Sch, Brigham & Womens Hosp, Heart & Vasc Ctr, Boston, MA 02115 USA. [Granger, Christopher B.; Lopes, Renato D.] Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC USA. [Vranckx, Pascal] Univ Hasselt, Hartctr Hasselt, Dept Cardiol & Crit Care Med, Hasselt, Belgium. [Vranckx, Pascal] Univ Hasselt, Fac Med & Life Sci, Hasselt, Belgium. [Montalescot, Gilles] Montpellier Univ, Univ Nimes Hosp, Cardiol Dept, ACTION Study Grp, Nimes, France. [Ten Berg, Jurien] St Antonius Hosp, Dept Cardiol, Nieuwegein, Netherlands. [Gersh, Bernard J.] Mayo Clin, Coll Med, Rochester, MN USA. [Angiolillo, Dominick J.] Univ Florida, Coll Med, Div Cardiol, Jacksonville, FL USA.-
local.publisher.placeNEW YORK-
local.type.refereedRefereed-
local.type.specifiedReview-
dc.identifier.doi10.1016/j.jacc.2019.05.016-
dc.identifier.isi000473259200013-
item.contributorCapodanno, Davide-
item.contributorHuber, Kurt-
item.contributorMehran, Roxana-
item.contributorLip, Gregory Y. H.-
item.contributorFaxon, David P.-
item.contributorGranger, Christopher B.-
item.contributorVRANCKX, Pascal-
item.contributorLopes, Renato D.-
item.contributorMontalescot, Gilles-
item.contributorCannon, Christopher P.-
item.contributorTen Berg, Jurien-
item.contributorGersh, Bernard J.-
item.contributorBhatt, Deepak L.-
item.contributorAngiolillo, Dominick J.-
item.fullcitationCapodanno, Davide; Huber, Kurt; Mehran, Roxana; Lip, Gregory Y. H.; Faxon, David P.; Granger, Christopher B.; VRANCKX, Pascal; Lopes, Renato D.; Montalescot, Gilles; Cannon, Christopher P.; Ten Berg, Jurien; Gersh, Bernard J.; Bhatt, Deepak L. & Angiolillo, Dominick J. (2019) Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI JACC State-of-the-Art Review. In: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 74(1), p. 83-99.-
item.fulltextWith Fulltext-
item.accessRightsRestricted Access-
item.validationecoom 2020-
crisitem.journal.issn0735-1097-
crisitem.journal.eissn1558-3597-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
10.1016@j.jacc.2019.05.016.pdf
  Restricted Access		Published version734.27 kBAdobe PDFView/Open    Request a copy
Show simple item record

SCOPUSTM   
Citations

36
checked on Sep 5, 2020

WEB OF SCIENCETM
Citations

118
checked on May 26, 2024

Page view(s)

122
checked on May 20, 2022

Download(s)

106
checked on May 20, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.